Boston, Massachusetts 02114


A Phase I Study of LXH254 in Patients With Advanced Solid Tumors That Harbor MAPK Pathway Alterations.


Inclusion Criteria: - All patients participating in this clinical trial must have progressed following standard therapy, or for whom, in the opinion of the Investigator, no effective standard therapy exists, is tolerated or appropriate. - Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 - Presence of at least one measurable lesion according to RECIST v1.1. - Documented MAPK alteration Additional inclusion criteria for the Dose Expansion part: LXH254 in combination with PDR001: - Patients with confirmed KRAS-mutated NSCLC - Patients with confirmed NRAS-mutated melanoma Exclusion Criteria: - Prior treatment with a BRAFi, MEKi and/or pan-RAF inihibitors for patients to be enrolled in the dose expansion part. Exceptions may be made after documented agreement between Novartis and Investigator. - History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO. - Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures. - Patients receiving proton pump inhibitors which cannot be discontinued 3 days prior to the start study treatment and for the duration of the study. - Pregnant or nursing (lactating) women Additional exclusion criteria for LXH254 in combination with PDR001 - History of severe hypersensitivity reactions, which in the opinion of the investigator may cause in increased risk of serious infusion reaction. - Known human immunodeficiency virus (HIV). - Any positive test for hepatitis B virus or hepatitis C virus indicating acute or chronic infection. - Active, known or suspected autoimmune disease. - Active infection requiring systemic antibiotic therapy - Patients requiring systemic steroid therapy or any immunosuppressive therapy (≥10mg/day prednisone or equivalent) which cannot be discontinued at least 7 days prior to first dose of study treatment. - Use of any live vaccines against infectious diseases within 4 weeks of initiation of study treatment. Other inclusion/exclusion criteria as per protocol may apply.



Primary Contact:

Study Director
Novartis Pharmaceuticals
Novartis Pharmaceuticals

Novartis Pharmaceuticals
Phone: 1-888-669-6682

Backup Contact:

Novartis Pharmaceuticals
Phone: +41613241111

Location Contact:

Boston, Massachusetts 02114
United States

There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source:

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.